Solitron Devices INC
Market Movers (8-K)
OTC.Pink
Solitron Devices announces a significant 101% increase in net sales for its fiscal 2027 first quarter, driven by a strong backlog and a return to profitability.
Better than expected
Delay expected
OTC.Pink
Solitron Devices, Inc. announced the results of its Annual Meeting of Stockholders held on April 24, 2026, including the election of a Class III director and ratification of independent auditors.
OTC.Pink
Solitron Devices announced preliminary unaudited fiscal 2026 fourth quarter results, showing significant net sales growth but a decrease in net bookings.
Capital raise
OTC.Pink
Solitron Devices, Inc. announced its annual meeting date and that its Board of Directors will explore potential merger or sale opportunities, citing strong demand for defense-related companies.
Delay expected
Better than expected
Capital raise
OTC.Pink
Solitron Devices, Inc. announced significant increases in net sales, bookings, and backlog for its fiscal 2026 third quarter.
OTC.Pink
Solitron Devices, Inc. announced record-breaking fiscal 2026 third-quarter bookings to date of $13.8 million, significantly exceeding previous year's figures.
Better than expected
Quarterly Earnings (10-Q)
OTC.Pink
Solitron Devices Inc. announces a significant turnaround in its first quarter of fiscal year 2026, reporting a net income of $990,000 compared to a net loss in the prior year, driven by a substantial increase in net sales.
Better than expected
OTC.Pink
Solitron Devices, Inc. reported a significant 49% increase in net sales for the third quarter of fiscal year 2026, driven by strong bookings and a doubling of its backlog, despite a decline in nine-month net income.
Worse than expected
OTC.Pink
Solitron Devices, Inc. reported a net loss of $234,000 for the three months ended August 31, 2025, and a $570,000 net loss for the six months, driven by decreased net sales and increased administrative expenses.
Worse than expected
Delay expected
OTC.Pink
Solitron Devices, Inc. reported a substantial 32% decrease in net sales and a shift to a net loss of $336,000 for the first quarter ended May 31, 2025, primarily due to lower backlog and delayed orders, though net bookings and total backlog saw significant increases.
Delay expected
Worse than expected
OTC.Pink
Solitron Devices saw a significant increase in net income for the third quarter of fiscal year 2025, primarily due to the acquisition of Micro Engineering Inc. (MEI).
Better than expected
OTC.Pink
Solitron Devices saw a significant increase in net sales for the second quarter of 2024, primarily driven by the acquisition of Micro Engineering Inc., but experienced a decrease in profitability due to higher costs.
Worse than expected
Annual Reports (10-K)
OTC.Pink
Solitron Devices, Inc. reported a 21% increase in net sales to $16.97 million for fiscal year 2026, driven by strong backlog growth despite ongoing internal control challenges.
OTC.Pink
Solitron Devices, Inc. announced a 10% increase in net sales and a 62% surge in backlog for fiscal year 2025, primarily driven by the acquisition of Micro Engineering Inc., though net income decreased significantly due to non-recurring gains in the prior fiscal year and identified material weaknesses in internal controls.
Capital raise
OTC.Pink
Solitron Devices experienced a significant increase in revenue and net income in fiscal year 2024, driven by the acquisition of Micro Engineering Inc. and a return to normal production levels.
Better than expected
Insider Trading (Form 4)
OTC.Pink
Olesen Value Fund L.P. reported changes in beneficial ownership of Solitron Devices Inc common stock on July 22, 2026.
OTC.Pink
Olesen Value Fund L.P. reported changes in beneficial ownership of Solitron Devices Inc common stock on July 17, 2026.
OTC.Pink
Olesen Value Fund L.P. reported transactions involving Solitron Devices Inc. common stock on July 8th and July 10th, 2026.
OTC.Pink
Olesen Value Fund L.P. reports multiple transactions of Solitron Devices Inc. common stock.
OTC.Pink
Olesen Value Fund L.P. reports significant transactions in Solitron Devices Inc. common stock.
OTC.Pink
Howard Timothy Eriksen, a Director and CEO of Solitron Devices Inc., reported a transaction involving common stock on June 5, 2026.
Proxy Statements (Def-14A)
OTC.Pink
Solitron Devices, Inc. announces its 2025 Annual Meeting of Stockholders for April 24, 2026, to vote on director election, auditor ratification, and executive compensation.
Worse than expected
OTC.Pink
Solitron Devices will provide a live audio stream of its 2024 Annual Meeting of Stockholders on January 24, 2025, for pre-registered shareholders.
OTC.Pink
Solitron Devices will hold its 2024 Annual Meeting of Stockholders on January 24, 2025, to vote on the election of directors, ratification of auditors, and executive compensation.
Schedule 13D - Activist Investments
OTC.Pink
Olesen Value Fund L.P. and associated entities have filed a Schedule 13D, reporting beneficial ownership of 10.1% of Solitron Devices Inc. common stock, acquired for investment purposes.
OTC.Pink
Olesen Value Fund L.P. has reduced its beneficial ownership in Solitron Devices Inc. to 11.5% while maintaining an investment purpose and seeking shareholder value discussions.
Worse than expected